Video
Dr. Cheng on Phase III Findings of Lenvatinib in HCC
Author(s):
Ann-Lii Cheng, MD, Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses the phase III trial of lenvatinib (Lenvima) compared with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
Ann-Lii Cheng, MD, Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses the phase III trial of lenvatinib (Lenvima) compared with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
HCC is one of the most difficult-to-treat cancers worldwide and is the second leading cause of cancer death, Cheng explains. In a phase III trial—the first which has shown positive findings in 10 years—lenvatinib was compared with the standard of care, sorafenib.
Lenvatinib was found to be associated with tumor shrinkage, prolonged duration of disease control, and an improvement in quality of life.
